- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Vivus Inc
+ Add to WatchlistVVUS:US
14.0001 USD 0.2401 1.74%
Share
As of 10:05:12 ET on 06/19/2013.
More on VVUS
News for Vivus Inc (VVUS)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Alex Denner Joins Vivus Activist Slate in Post-Icahn Move
- Vivus Adds Two New Directors to Board Amid Pressure
- The Top Ten Stocks for Monday, May 13
- Vivus Is in Talks With Potential Marketing Partners
- Arena’s FDA-Approved Weight Loss Pill Clears DEA Hurdle
- Arena Withdrawing Obesity Drug Regulatory Application in Europe
- Vivus Jumps as FDA Allows Wider Sales of Obesity Drug
- U.S. Stock Options With Biggest Changes in Implied Volatility
- Arena Joins Vivus Finding Obesity Drugs Fizzle on Costs
- Nasdaq Short Interest by Industries as of Feb. 28
- Largest Nasdaq Short Interest Positions as of Feb. 28
- Nasdaq Short Interest by Industries as of Feb. 15
- Largest Nasdaq Short Interest Positions as of Feb. 15
- U.S. Stock Options With Biggest Changes in Implied Volatility
- The Top Ten Stocks for Tuesday, February 26
- VIVUS Announces Study Results Showing STENDRA (Avanafil) is Effective for Sexual Activity Within 15 Minutes in Men With Erectile Published 1 hour ago
- VIVUS Posts Investor Presentation Published 4 hours ago
- Open Letter to Vivus Employees Released by First Manhattan Co. Published Jun 17, 2013
- New Review Article Discusses Complications-Centric Approach to Obesity Medical Management With Qsymia Published Jun 17, 2013
- VIVUS Urges Stockholders to Support the Board of Directors and Management Team at This Critical Time Published Jun 17, 2013
- VIVUS Announces Scientific Presentations Published Jun 15, 2013
- VIVUS to Present at Upcoming Investor Conference Published Jun 12, 2013
- New Article Discusses Treatment Options for Weight Management in People With Type 2 Diabetes Published Jun 07, 2013
- VIVUS Files Definitive Proxy Materials With SEC Published Jun 05, 2013
- First Manhattan Mails Definitive Proxy Statement and Sends Letter to Vivus Stockholders Published Jun 05, 2013
- VIVUS Announces Scientific Presentations Published Jun 03, 2013
- First Manhattan Adds Alex Denner to Vivus Board Slate Published May 23, 2013
- VIVUS Announces Scientific Presentations Published May 22, 2013
- Lundbeck Fined $125.6 Million by EU Drug Delay Probe Updated 2 hours ago
- Marathon Patent, Novo Nordisk: Intellectual Property Updated 3 hours ago
- Swiss Stocks Decline Before Fed Statement on Stimulus
- Almirall CEO on International Expansion, Porfolio
- Almirall CEO Eyes $11.6 Billion COPD Market Smokers Fuel
- Medtronic’s Infuse No Better Than Bone Graft With Risk
- FDA Investigating Lilly’s Zyprexa Injection After Two Die
- Global Power Players: In The Loop (06/14)
- The Top Ten Stocks for Tuesday, June 18
- Glaxo Gets Offer for Heart Drugs With Declining Sales
- Royalty Pharma Drops Judicial Review Request of Elan Bid
- Arnold & Porter, Skadden, Cravath, Willkie: Business of Law
- Drugmakers Opened to ‘Pay for Delay’ Suits by High Court
- The Top Ten Stocks for June 17
- J&J to Buy Aragon Pharmaceuticals for Cancer Candidate
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page